For instance, the FDA has recently approved the use of immunotherapy in conjunction with chemotherapy across all strata of tumor PD-L1 expression levels, after overall survival (OS) was shown to improve with treatment, even among those with <1% tumor PD-L1 expression [15,16,17]. Here, CD274 is linked to neoplasm.